Concepts of disease severity, activity, control and responsiveness to treatment are linked but different. Severity refers to the loss of function of the organs induced by the disease process or to the occurrence of severe acute exacerbations. Severity may vary over time and needs regular follow-up. Control is the degree to which therapy goals are currently met. These concepts have evolved over time for asthma in guidelines, task forces or consensus meetings. The aim of this paper is to generalize the approach of the uniform definition of severe asthma presented to WHO for chronic allergic and associated diseases (rhinitis, chronic rhinosinusitis, chronic urticaria and atopic dermatitis) in order to have a uniform definition of severity, control and risk, usable in most situations. It is based on the appropriate diagnosis, availability and accessibility of treatments, treatment responsiveness and associated factors such as comorbidities and risk factors. This uniform definition will allow a better definition of the phenotypes of severe allergic (and related) diseases for clinical practice, research (including epidemiology), public health purposes, education and the discovery of novel therapies.

Keywords:
Immunoglobulin E, Asthma, Rhinitis, Rhinosinusitis, Urticaria, Atopic dermatitis
1.
Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al: Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004;113:832–836.
2.
Bousquet J, Anto JM, Bachert C, Bousquet PJ, Colombo P, Crameri R, et al: Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA2LEN project. Allergy 2006;61:671–680.
3.
Svanes C, Sunyer J, Plana E, Dharmage S, Heinrich J, Jarvis D, et al: Early life origins of chronic obstructive pulmonary disease. Thorax 2010;65:14–20.
4.
Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al: Second symposium on the definition and management of anaphylaxis: summary report – Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391–397.
5.
Demoly P, Pichler W, Pirmohamed M, Romano A: Important questions in Allergy. 1. Drug allergy/hypersensitivity. Allergy 2008;63:616–619.
6.
Sicherer SH, Sampson HA: Food allergy. J Allergy Clin Immunol 2010;125(suppl 2):S116–S125.
7.
Bilo BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JN: Diagnosis of hymenoptera venom allergy. Allergy 2005;60:1339–1349.
8.
Zuraw BL: Clinical practice: hereditary angioedema. N Engl J Med 2008;359:1027–1036.
9.
Krause K, Zuberbier T, Maurer M: Modern approaches to the diagnosis and treatment of cold contact urticaria. Curr Allergy Asthma Rep 2010;10:243–249.
10.
Roujeau JC: Clinical heterogeneity of drug hypersensitivity. Toxicology 2005;209:123–129.
11.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(suppl 86):8–160.
12.
Bousquet J, Khaltaev N: Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: A Comprehensive Approach. World Health Organization, 2007, p 148.
13.
Bieber T: Atopic dermatitis. N Engl J Med 2008;358:1483–1494.
14.
Pearce N, Pekkanen J, Beasley R: How much asthma is really attributable to atopy? Thorax 1999;54:268–272.
15.
Weinmayr G, Forastiere F, Weiland SK, Rzehak P, Abramidze T, Annesi-Maesano I, et al: International variation in prevalence of rhinitis and its relationship with sensitisation to perennial and seasonal allergens. Eur Respir J 2008;32:1250–1261.
16.
Bousquet PJ, Leynaert B, Neukirch F, Sunyer J, Janson CM, Anto J, et al: Geographical distribution of atopic rhinitis in the European Community Respiratory Health Survey I. Allergy 2008;63:1301–1309.
17.
Bousquet J, Fokkens W, Burney P, Durham SR, Bachert C, Akdis CA, et al: Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy 2008;63:842–853.
18.
Fokkens W, Lund V, Mullol J: EP3OS. European position paper on rhinosinusitis and nasal polyps. Rhinology 2007;45(suppl 20):1–139.
19.
Bachert C, Van Bruaene N, Toskala E, Zhang N, Olze H, Scadding G, et al: Important research questions in allergy and related diseases: 3-chronic rhinosinusitis and nasal polyposis – a GALEN study. Allergy 2009;64:520–533.
20.
Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, Bockelbrink A, et al: Chronic rhinosinusitis in Europe – an underestimated disease. A GA2LEN study. Allergy 2011;66:1216–1223.
21.
Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gimenez-Arnau A, et al: EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009;64:1417–1426.
22.
Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gimenez-Arnau AM, et al: EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64:1427–1443.
23.
Expert panel report 3: Guidelines for the diagnosis and management of asthma. National Asthma Education and Prevention Program. National Heart, Lung and Blood Institute. US Department of Health and Human Services, 2007; p 440.
24.
Bousquet J, Clark TJ, Hurd S, Khaltaev N, Lenfant C, O’Byrne P, et al: GINA guidelines on asthma and beyond. Allergy 2007;62:102–112.
25.
American Thoracic Society: Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000;162:2341–2351.
26.
Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, et al: A new perspective on concepts of asthma severity and control. Eur Respir J 2008;32:545–554.
27.
Global Strategy for Asthma Management and Prevention (GINA), 2010 update. http://wwwginasthmaorg/pdf/GINA_Report_ 2010pdf, 2010.
28.
Bousquet J, Mantzouranis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, Bleecker ER, et al: Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010;126:926–938.
29.
Bousquet J, Anto JM, Sterk PJ, Adcock IM, Chung KF, Roca J, et al: Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Med 2011;3:43.
30.
Humbert M, Holgate S, Boulet LP, Bousquet J: Asthma control or severity: that is the question. Allergy 2007;62:95–101.
31.
Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, Fitzgerald M, et al: Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143–178.
32.
Thomas M, Gruffydd-Jones K, Stonham C, Ward S, Macfarlane TV: Assessing asthma control in routine clinical practice: use of the Royal College of Physicians ‘3 questions’. Prim Care Respir J 2009;18:83–88.
33.
Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR: Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902–907.
34.
Juniper EF, Bousquet J, Abetz L, Bateman ED: Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire. Respir Med 2006;100:616–621.
35.
Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al: Development of the Asthma Control Test: a survey for assessing asthma control. J Allergy Clin Immunol 2004;113:59–65.
36.
Thomas M, Kay S, Pike J, Williams A, Rosenzweig JR, Hillyer EV, et al: The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respir J 2009;18:41–49.
37.
Juniper EF, Gruffydd-Jones K, Ward S, Svensson K: Asthma Control Questionnaire in children: validation, measurement properties, interpretation. Eur Respir J 2010;36:1410–1416.
38.
Liu AH, Zeiger RS, Sorkness CA, Ostrom NK, Chipps BE, Rosa K, et al: The Childhood Asthma Control Test: retrospective determination and clinical validation of a cut point to identify children with very poorly controlled asthma. J Allergy Clin Immunol 2010;126:267–273.
39.
British Thoracic Society Scottish Intercollegiate Guidelines Network: British guideline on the management of asthma. Thorax 2008;63(suppl 4):iv1–iv121.
40.
Haahtela T, Tuomisto LE, Pietinalho A, Klaukka T, Erhola M, Kaila M, et al: A 10-year asthma programme in Finland: major change for the better. Thorax 2006;61:663–670.
41.
Souza-Machado C, Souza-Machado A, Franco R, Ponte EV, Barreto ML, Rodrigues LC, et al: Rapid reduction in hospitalisations after an intervention to manage severe asthma. Eur Respir J 2010;35:515–521.
42.
Andrade WC, Camargos P, Lasmar L, Bousquet J: A pediatric asthma management program in a low-income setting resulting in reduced use of health service for acute asthma. Allergy 2010;65:1472–1477.
43.
Evans R 3rd, Gergen PJ, Mitchell H, Kattan M, Kercsmar C, Crain E, et al: A randomized clinical trial to reduce asthma morbidity among inner-city children: results of the National Cooperative Inner-City Asthma Study. J Pediatr 1999;135:332–338.
44.
Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309–316.
45.
Bell E, Sousa A, Fleming L, Bush A, Chung K, Versnel I, et al: Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicines Initative (IMI). Thorax 2011;66:910–917.
46.
Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD: A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 2000;162(4 Pt. 1):1403–1406.
47.
Devulapalli CS, Carlsen KC, Haland G, Munthe-Kaas MC, Pettersen M, Mowinckel P, et al: Severity of obstructive airways disease by age 2 years predicts asthma at 10 years of age. Thorax 2008;63:8–13.
48.
Brand PL, Baraldi E, Bisgaard H, Boner AL, Castro-Rodriguez JA, Custovic A, et al: Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J 2008;32:1096–1110.
49.
Bousquet J, Anto J, Auffray C, Akdis M, Cambon-Thomsen A, Keil T, et al: MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy 2011;66:596–604.
50.
Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R: Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 2009;373:240–249.
51.
Bousquet J, Bachert C, Canonica GW, Casale TB, Cruz AA, Lockey RJ, et al: Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol 2009;124:428–433.
52.
Bousquet PJ, Combescure C, Neukirch F, Klossek JM, Mechin H, Daures JP, et al: Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy 2007;62:367–372.
53.
Ragab SM, Lund VJ, Saleh HA, Scadding G: Nasal nitric oxide in objective evaluation of chronic rhinosinusitis therapy. Allergy 2006;61:717–724.
54.
Valero A, Ferrer M, Sastre J, Navarro AM, Monclus L, Marti-Guadano E, et al: A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items. J Allergy Clin Immunol 2007;120:359–365.
55.
Baiardini I, Bousquet PJ, Brzoza Z, Canonica GW, Compalati E, Fiocchi A, et al: Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. Allergy 2010;65:290–295.
56.
Schatz M, Meltzer EO, Nathan R, Derebery MJ, Mintz M, Stanford RH, et al: Psychometric validation of the rhinitis control assessment test: a brief patient-completed instrument for evaluating rhinitis symptom control. Ann Allergy Asthma Immunol 2010;104:118–124.
57.
Bousquet PJ, Combescure C, Klossek JM, Daures JP, Bousquet J: Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis. J Allergy Clin Immunol 2009;123:1349–1354.
58.
Ryan D, van Weel C, Bousquet J, Toskala E, Ahlstedt S, Palkonen S, et al: Primary care: the cornerstone of diagnosis of allergic rhinitis. Allergy 2008;63:981–989.
59.
Bousquet J, van Cauwenberge P, Khaltaev N (eds): ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy: allergic rhinitis and its impact on asthma. Allergy 2004;59:373–387.
60.
Bousquet J, Annesi-Maesano I, Carat F, Leger D, Rugina M, Pribil C, et al: Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy 2005;35:728–732.
61.
Bousquet PJ, Bachert C, Canonica GW, Casale TB, Mullol J, Klossek JM, et al: Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. J Allergy Clin Immunol 2010;126:666–668.
62.
Bousquet J, Lund VJ, Van Cauwenberge P, Bremard-Oury C, Mounedji N, Stevens MT, et al: Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial. Allergy 2003;58:733–741.
63.
Webb DR, Meltzer EO, Finn AF Jr, Rickard KA, Pepsin PJ, Westlund R, et al: Intranasal fluticasone propionate is effective for perennial nonallergic rhinitis with or without eosinophilia. Ann Allergy Asthma Immunol 2002;88:385–390.
64.
Greiner AN, Meltzer EO: Pharmacologic rationale for treating allergic and nonallergic rhinitis. J Allergy Clin Immunol 2006;118:985–998.
65.
Bousquet J, Van Cauwenberge P, Khaltaev N: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(suppl 5):S147–S334.
66.
Rondon C, Romero JJ, Lopez S, Antunez C, Martin-Casanez E, Torres MJ, et al: Local IgE production and positive nasal provocation test in patients with persistent nonallergic rhinitis. J Allergy Clin Immunol 2007;119:899–905.
67.
Dykewicz MS, Fineman S: Executive summary of joint task force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol 1998;81:463–468.
68.
Bousquet J, Neukirch F, Bousquet PJ, Gehano P, Klossek JM, Le Gal M, et al: Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006;117:158–162.
69.
Blaiss MS: Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr Med Res Opin 2004;20:1937–1952.
70.
Simons FE: Learning impairment and allergic rhinitis. Allergy Asthma Proc 1996;17:185–189.
71.
Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, et al: Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 2010;65:459–466.
72.
Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, et al: Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008;372:1049–1057.
73.
Lim M, Lew-Gor S, Darby Y, Brookes N, Scadding G, Lund VJ: The relationship between subjective assessment instruments in chronic rhinosinusitis. Rhinology 2007;45:144–147.
74.
Van Zele T, Claeys S, Gevaert P, Van Maele G, Holtappels G, Van Cauwenberge P, et al: Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 2006;61:1280–1289.
75.
Zhang N, Van Zele T, Perez-Novo C, Van Bruaene N, Holtappels G, Deruyck N, et al: Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol 2008;122:961–968.
76.
Van Bruaene N, Derycke L, Perez-Novo CA, Gevaert P, Holtappels G, De Ruyck N, et al: TGF-beta signaling and collagen deposition in chronic rhinosinusitis. J Allergy Clin Immunol 2009;124:253–259.
77.
Stjarne P, Blomgren K, Caye-Thomasen P, Salo S, Soderstrom T: The efficacy and safety of once-daily mometasone furoate nasal spray in nasal polyposis: a randomized, double-blind, placebo-controlled study. Acta Otolaryngol 2006;126:606–612.
78.
Mullol J, Obando A, Pujols L, Alobid I: Corticosteroid treatment in chronic rhinosinusitis: the possibilities and the limits. Immunol Allergy Clin North Am 2009;29:657–668.
79.
Vaidyanathan S, Barnes M, Williamson P, Hopkinson P, Donnan PT, Lipworth B: Treatment of chronic rhinosinusitis with nasal polyposis with oral steroids followed by topical steroids: a randomized trial. Ann Intern Med 2011;154:293–302.
80.
Vento SI, Ertama LO, Hytonen ML, Wolff CH, Malmberg CH: Nasal polyposis: clinical course during 20 years. Ann Allergy Asthma Immunol 2000;85:209–214.
81.
Alobid I, Guilemany JM, Mullol J: Nasal manifestations of systemic illnesses. Curr Allergy Asthma Rep 2004;4:208–216.
82.
Bachert C, Zhang N, Holtappels G, De Lobel L, van Cauwenberge P, Liu S, et al: Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol 2010;126:962–968.
83.
Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, et al: Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) – classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy 2011;66:818–829.
84.
Fuchs HA, Tanner SB: Granulomatous disorders of the nose and paranasal sinuses. Curr Opin Otolaryngol Head Neck Surg 2009;17:23–27.
85.
Bonfils P, Halimi P, Malinvaud D: Adrenal suppression and osteoporosis after treatment of nasal polyposis. Acta Otolaryngol 2006;126:1195–1200.
86.
Kaplan AP, Greaves M: Pathogenesis of chronic urticaria. Clin Exp Allergy 2009;39:777–787.
87.
Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet P, Bousquet J, et al: Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011;66:317–330.
88.
Mathias SD, Dreskin SC, Kaplan A, Saini SS, Spector S, Rosen KE: Development of a daily diary for patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2010;105:142–148.
89.
Mlynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M: How to assess disease activity in patients with chronic urticaria? Allergy 2008;63:777–780.
90.
Baiardini I, Braido F, Brandi S, Canonica GW: Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol 2006;97:419–430.
91.
Kropfl L, Maurer M, Zuberbier T: Treatment strategies in urticaria. Expert Opin Pharmacother 2010;11:1445–1450.
92.
Neven B, Prieur AM, Quartier dit Maire P: Cryopyrinopathies: update on pathogenesis and treatment. Nat Clin Pract Rheumatol 2008;4:481–489.
93.
Soubrier M: Schnitzler syndrome. Joint Bone Spine 2008;75:263–266.
94.
Valent P, Arock M, Bischoff SC, Buhring HJ, Brockow K, Escribano L, et al: The European Competence Network on Mastocytosis (ECNM). Wien Klin Wochenschr 2004;116:647–651.
95.
Magerl M, Borzova E, Gimenez-Arnau A, Grattan CE, Lawlor F, Mathelier-Fusade P, et al: The definition and diagnostic testing of physical and cholinergic urticarias – EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy 2009;64:1715–1721.
96.
Dreskin SC, Andrews KY: The thyroid and urticaria. Curr Opin Allergy Clin Immunol 2005;5:408–412.
97.
Willemsen R, Roseeuw D, Vanderlinden J: Alexithymia and dermatology: the state of the art. Int J Dermatol 2008;47:903–910.
98.
Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23–31.
99.
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M: The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001;10:11–18.
100.
Schmitt J, Langan S, Williams HC: What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol 2007;120:1389–1398.
101.
Rajka G, Langeland T: Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989;144:13–14.
102.
Stalder JF, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, et al: Patient-oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy 2011;66:1114–1121.
103.
van Velsen SG, Knol MJ, Haeck IM, Bruijnzeel-Koomen CA, Pasmans SG: The Self-administered Eczema Area and Severity Index in children with moderate to severe atopic dermatitis: better estimation of AD body surface area than severity. Pediatr Dermatol 2010;27:470–475.
104.
Alanne S, Nermes M, Soderlund R, Laitinen K: Quality of life in infants with atopic dermatitis and healthy infants: a follow-up from birth to 24 months. Acta Paediatr 2011;100:65–70.
105.
Rehal B, Armstrong A: Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985–2010. PLoS One 2011;6:e17520.
106.
Saeki H, Furue M, Furukawa F, Hide M, Ohtsuki M, Katayama I, et al: Guidelines for management of atopic dermatitis. J Dermatol 2009;36:563–577.
107.
Darsow U, Wollenberg A, Simon D, Taieb A, Werfel T, Oranje A, et al: ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010;24:317–328.
108.
Bos JD: Atopiform dermatitis. Br J Dermatol 2002;147:426–429.
109.
Filipovich A, McClain K, Grom A: Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant 2010;16(suppl 1):S82–S89.
110.
Clark RA, Fuhlbrigge RC: Immunology and skin disease 2009: frontiers in cutaneous immunology. J Invest Dermatol 2009;129:1849–1851.
111.
Leung DY: Preface to atopic dermatitis intervention to control the atopic march. J Allergy Clin Immunol 2003;112(suppl 6):S117.
112.
Illi S, von Mutius E, Lau S, Nickel R, Gruber C, Niggemann B, et al: The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol 2004;113:925–931.
113.
Spergel JM: Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin North Am 2010;30:269–280.
114.
Brown SJ, Asai Y, Cordell HJ, Campbell LE, Zhao Y, Liao H, et al: Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J Allergy Clin Immunol 2011;127:661–667.
115.
von Bubnoff D, Andres E, Hentges F, Bieber T, Michel T, Zimmer J: Natural killer cells in atopic and autoimmune diseases of the skin. J Allergy Clin Immunol 2010;125:60–68.
116.
Ong PY, Leung DY: The infectious aspects of atopic dermatitis. Immunol Allergy Clin North Am 2010;30:309–321.
117.
Shiohara T, Sato Y, Takahashi R, Kurata M, Mizukawa Y: Increased susceptibility to cutaneous viral infections in atopic dermatitis: the roles of regulatory T cells and innate immune defects. Curr Probl Dermatol 2011;41:125–135.
118.
Fonacier LS, Aquino MR: The role of contact allergy in atopic dermatitis. Immunol Allergy Clin North Am 2010;30:337–350.
119.
Lang A, Carlsen KH, Haaland G, Devulapalli CS, Munthe-Kaas M, Mowinckel P, et al: Severe asthma in childhood: assessed in 10 year olds in a birth cohort study. Allergy 2008;63:1054–1060.
120.
Lang A, Mowinckel P, Sachs-Olsen C, Riiser A, Lunde J, Carlsen KH, et al: Asthma severity in childhood, untangling clinical phenotypes. Pediatr Allergy Immunol 2010;21:945–953.
121.
Fitzpatrick AM, Teague WG, Meyers DA, Peters SP, Li X, Li H, et al: Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol 2011;127:382–389.
122.
Lodrup Carlsen KC, Hedlin G, Bush A, Wennergren G, de Benedictis FM, De Jongste JC, et al: Assessment of problematic severe asthma in children. Eur Respir J 2011;37:432–440.
123.
Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A: Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007;120:381–387.
124.
Balzar S, Fajt ML, Comhair SA, Erzurum SC, Bleecker E, Busse WW, et al: Mast cell phenotype, location, and activation in severe asthma: data from the severe asthma research program. Am J Respir Crit Care Med 2011;183:299–309.
125.
Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al: Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010;181:315–323.
126.
Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ: An integrative systems biology approach to understanding pulmonary diseases. Chest 2010;137:1410–1416.
127.
Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al: Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011;127:355–360.
128.
Brasier AR, Victor S, Boetticher G, Ju H, Lee C, Bleecker ER, et al: Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. J Allergy Clin Immunol 2008;121:30–37.
129.
Miller MK, Johnson C, Miller DP, Deniz Y, Bleecker ER, Wenzel SE: Severity assessment in asthma: an evolving concept. J Allergy Clin Immunol 2005;116:990–995.
130.
Wenzel SE: Asthma: defining of the persistent adult phenotypes. Lancet 2006;368:804–813.
131.
ten Brinke A, Sterk PJ, Masclee AA, Spinhoven P, Schmidt JT, Zwinderman AH, et al: Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005;26:812–818.
132.
Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al: Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178:218–224.
133.
Auffray C, Charron D, Hood L: Predictive, preventive, personalized and participatory medicine: back to the future. Genome Med 2010;2:57.
134.
Bousquet J, Schunemann HJ, Bousquet PJ, Bachert C, Canonica GW, Casale TB, et al: How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2)LEN statement. Allergy 2011;66:765–774.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.